TransMedics price target lowered to $80 from $99 at Canaccord

Canaccord lowered the firm’s price target on TransMedics to $80 from $99 and keeps a Buy rating on the shares. The firm said they posted yet another strong beat-and-raise with product sales outperforming, but the big upside derived from services but the target reflects comp group compression.